Identify the deaminase source of mutations that potentially inactivate the virus, and may result in new viral strains.
Define the specific COVID-19 deaminase binding sites that can potentially be new drug 'pockets'.
THE CONTRIBUTION WE WILL MAKE TO THE COVID-19 RESPONSE
GMDx IIF profiling tools are immediately available to reveal new insights into COVID-19.
Chronic Hepatitis B (cHBV)
Established the Innate Immune Profile Score that:
Identify patients who can safely stop antiviral therapy
Identify patients who should remain on antiviral therapy due to a high likelihood of relapse (i.e. with compromised innate immune system)
Flavivirus Host-Parasite Study
GMDx was the first to show that the host virus relationship is characterised by the host's deaminase-associated mutations hat attack viruses - and give rise to viral strain diversity.